Taiho's RECOURSE Trial Meets Primary Endpoint for mCRC in Phase 3

Taiho Pharmaceutical Co., parent company of Taiho Oncology, announced recently that its combination drug for refractory metastatic colorectal cancer met its primary endpoint in a phase 3 global RECOURSE trial.
Published Online: June 09, 2014

The RECOURSE trial of the combined oral drugs trifluridine and tipiracil hydrochloride (TAS-102) is a global, randomized, double blind, placebo-controlled study of 800 people with refractory mCRC. Each participant had received at least two prior failed treatment attempts using standard chemotherapy and received either TAS-102 or placebo to establish the efficacy and toleration of the drug combination and improve overall survival.

“We are very pleased by the results from the phase 3 RECOURSE trial in refractory mCRC, which support TAS-102 as a potential new treatment option for this patient population,” Fabio M. Benedetti, MD, senior vice president and chief medical officer at Taiho Oncology, said in a press release.

Report: http://bit.ly/1hK7lQD
Source: Healio



Compendia
COPD Compendium
Dermatology Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST
$AD300x250BB$